In addition, some studies have showed that patients could receive granulocyte–macrophage colony-stimulating factor (GM-CSF) or granulocyte colony-stimulating factor (G-CSF) treatment to decrease the duration of neutropenia, but this approach remains controversial [25–27]. This evidence concerns the gene CSF2 and Decreased total neutrophil count.